Chemoinformaics analysis of Malonylginsenoside rc
| Molecular Weight | 706.65 | nRot | 11 |
| Heavy Atom Molecular Weight | 668.346 | nRig | 19 |
| Exact Molecular Weight | 706.211 | nRing | 4 |
| Solubility: LogS | -2.474 | nHRing | 2 |
| Solubility: LogP | 2.774 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 88 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 50 | No. of Aromatic Carbocycles | 1 |
| nHetero | 17 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 1 |
| No. of Hydrogen atom | 38 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 33 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 17 | No. of Arom Bond | 6 |
| nHA | 17 | APOL | 94.0821 |
| nHD | 2 | BPOL | 58.9539 |
| QED | 0.699 |
| Synth | 3.575 |
| Natural Product Likeliness | 1.525 |
| NR-PPAR-gamma | 0.007 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.165 |
| Pgp-sub | 0.027 |
| HIA | 0.005 |
| CACO-2 | -4.607 |
| MDCK | 0.0000133 |
| BBB | 0.991 |
| PPB | 0.802651 |
| VDSS | 3.175 |
| FU | 0.189 |
| CYP1A2-inh | 0.71 |
| CYP1A2-sub | 0.938 |
| CYP2c19-inh | 0.55 |
| CYP2c19-sub | 0.941 |
| CYP2c9-inh | 0.071 |
| CYP2c9-sub | 0.785 |
| CYP2d6-inh | 0.968 |
| CYP2d6-sub | 0.915 |
| CYP3a4-inh | 0.597 |
| CYP3a4-sub | 0.789 |
| CL | 9.939 |
| T12 | 0.569 |
| hERG | 0.104 |
| Ames | 0.953 |
| ROA | 0.836 |
| SkinSen | 0.14 |
| Carcinogencity | 0.092 |
| EI | 0.01 |
| Respiratory | 0.948 |
| NR-Aromatase | 0.041 |
| Antiviral | Yes |
| Prediction | 0.64254 |